OR WAIT 15 SECS
Leading Biopharma Company Adopts Medidata Technology to Bring Operational Efficiencies and Greater Speed to Innovative Clinical Study on Metabolic Disorders
Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that TWi Biotechnology, Inc. has selected the Medidata Clinical Cloud® to enhance the speed, quality and productivity of its novel clinical study on metabolic disorders.
TWi Biotechnology, Inc., a fully owned subsidiary of TWi Pharmaceuticals, Inc. based in Taipei, Taiwan, specializes in the development of innovative new drugs for unmet medical needs, especially in the diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. To optimize a Phase II study on metabolic disorders, TWi Biotechnology is implementing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®).
Read the full release here.